UTHR - United Therapeutics Corporation Stock Price, News & Analysis

$125.41 0.00 (0.00 %)
(As of 11/24/2017 11:43 AM ET)
Previous Close$125.41
Today's Range$124.78 - $126.64
52-Week Range$112.01 - $169.89
Volume259,400 shs
Average Volume562,124 shs
Market Capitalization$5.37 billion
P/E Ratio11.06
Dividend YieldN/A
Beta1.38

About United Therapeutics Corporation (NASDAQ:UTHR)

United Therapeutics Corporation logoUnited Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca). The Company markets and sells an oncology product in the United States, Unituxin (dinutuximab) Injection (Unituxin), which is approved for treatment of neuroblastoma. The Company is also engaged in early-stage research and development of a number of organ transplantation-related technologies.


Industry, Sector and Symbol

Industry Biotechnology & Medical Research
Sub-IndustryBiotechnology
SectorHealthcare
SymbolNASDAQ:UTHR
CUSIP91307C10

Debt

Debt-to-Equity RatioN/A
Current Ratio2.08%
Quick Ratio1.93%

Price-To-Earnings

Trailing P/E Ratio11.06
Forward P/E Ratio10.20
P/E GrowthN/A

Sales & Book Value

Annual Sales$1.60 billion
Price / Sales3.39
Cash Flow$17.56 per share
Price / Cash7.14
Book Value$47.90 per share
Price / Book2.62

Dividend

Annual DividendN/A
Dividend YieldN/A

Profitability

Trailing EPS$11.34
Net Income$713.70 million
Net Margins30.50%
Return on Equity26.24%
Return on Assets19.37%

Miscellaneous

Employees750
Outstanding Shares43,210,000

Frequently Asked Questions for United Therapeutics Corporation (NASDAQ:UTHR)

What is United Therapeutics Corporation's stock symbol?

United Therapeutics Corporation trades on the NASDAQ under the ticker symbol "UTHR."

How will United Therapeutics Corporation's stock buyback program work?

United Therapeutics Corporation declared that its board has initiated a share buyback program on Sunday, June 4th 2017, which authorizes the company to repurchase $250,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to repurchase up to 4.6% of its shares through open market purchases. Shares repurchase programs are usually an indication that the company's board of directors believes its shares are undervalued.

How were United Therapeutics Corporation's earnings last quarter?

United Therapeutics Corporation (NASDAQ:UTHR) announced its earnings results on Wednesday, October, 25th. The biotechnology company reported $6.27 EPS for the quarter, beating analysts' consensus estimates of $4.01 by $2.26. The biotechnology company had revenue of $445.50 million for the quarter, compared to analysts' expectations of $426.43 million. United Therapeutics Corporation had a net margin of 30.50% and a return on equity of 26.24%. The firm's revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the business earned $4.23 EPS. View United Therapeutics Corporation's Earnings History.

When will United Therapeutics Corporation make its next earnings announcement?

United Therapeutics Corporation is scheduled to release their next quarterly earnings announcement on Wednesday, February, 28th 2018. View Earnings Estimates for United Therapeutics Corporation.

Where is United Therapeutics Corporation's stock going? Where will United Therapeutics Corporation's stock price be in 2017?

11 brokers have issued 12-month target prices for United Therapeutics Corporation's shares. Their forecasts range from $95.00 to $213.00. On average, they anticipate United Therapeutics Corporation's stock price to reach $135.50 in the next year. View Analyst Ratings for United Therapeutics Corporation.

What are Wall Street analysts saying about United Therapeutics Corporation stock?

Here are some recent quotes from research analysts about United Therapeutics Corporation stock:

  • 1. According to Zacks Investment Research, "United Therapeutics holds a strong position in the PAH market with four approved products targeting this indication. Lately, the growth of its PAH drugs Orenitram, Tyvaso and Remodulin have slowed due to competition from Uptravi and Adcirca + Letairis combination therapy. Also, recently, the company announced that regulatory issues will delay the U.S. launch of RemoSynch. The company is working on new delivery mechanisms for Remodulin and expanded indications for its other marketed products like Orenitram and Tyvaso, which might drive long-term growth. Though Orenitram sales growth was slow in 2016, management estimates the drug to have $1 billion peak revenue potential. Shares also underperformed the industry this year so far. Estimates have remained stable ahead of the Q3 earnings release. The company has a mixed record of earnings surprises in the recent quarters." (10/9/2017)
  • 2. Cowen Inc analysts commented, "1Q Revenues were weak across the prostacyclin PAH franchise." (4/26/2017)
  • 3. Credit Suisse Group analysts commented, "The recent acquisition of UTHR's competitor has driven a large M&A premium in UTHR shares, and we see downside due to potential near-term and generic risk starting late 2017-2018. United Therapeutics' product franchise consists of pulmonary arterial hypertension (PAH) therapies. PAH is essentially high blood pressure in the lungs. We think an acquisition for United Therapeutics is unlikely in the near term since the company has mentioned doing deals to acquire. We see catalysts in the coming month that could lead to downside in shares, especially with shares trading above (~20%), the level at which we see the fundamental value of the company. In the long term, we remain more cautious on what the current valuation would suggest around risk to UTHR's PAH franchise from generics launching as early as 2018. We think that the stock trades at a higher non-GAAP P/E multiple than what consensus actually shows; we estimate 2018 and 2019 P/E multiples of 15x and 20x vs. consensus of 10x and 11x, respectively." (3/16/2017)
  • 4. Jefferies Group LLC analysts commented, "Our physician poll indicates continuing competitor Uptravi impact on UTHR's treprostinil franchise & meaningful headwinds from generic Remodulin - potentially ~35% of current sales at risk. Yet, current consensus est's do not reflect such downside risks, particularly a potential real threat from generic Remodulin in 2018. Downgrading UTHR to Underperform from Hold, but keeping $116 PT." (3/6/2017)
  • 5. Wedbush analysts commented, "With consistent YoY growth in revenues, free cash flow and a deep pipeline of diverse assets in late-stage development, we continue to believe UTHR continues to be an attractive long-term investment. ' Q4 and 2016 top and bottom line missed on seasonal choppiness and transient warehousing of Remodulin and Tyvaso patients. Reported Q4/FY:16 revenues of $409MM/$1599MM came in below consensus estimates of $416MM/$1605MM. GAAP EPS of $2.43/$15.25 also missed consensus estimates of $3.68/$16.46. While Remodulin and Adcirca beat, Tyvaso and Orenitram missed. Management indicated their view that patient warehousing with oral PAH medications is transient and anticipates sales acceleration for Tyvaso and Remodulin later in 2017 as the effect of oral PAH medications begins to wane and PAH patients need a new medication. UTHR ended 2016 with ~$1.053BN in cash & cash eq. Management implied that instead of pursing another share buyback, they may announce business development activities." (2/27/2017)

Who are some of United Therapeutics Corporation's key competitors?

Who are United Therapeutics Corporation's key executives?

United Therapeutics Corporation's management team includes the folowing people:

  • Martine A. Rothblatt Ph.D. J.D., Chairman of the Board, Chief Executive Officer (Age 62)
  • Michael Benkowitz, President, Chief Operating Officer (Age 45)
  • Christopher Patusky J.D., Lead Independent Vice Chairman of the Board (Age 53)
  • James C. Edgemond, Chief Financial Officer, Treasurer (Age 49)
  • Paul A. Mahon J.D., Executive Vice President, General Counsel, Corporate Secretary (Age 53)
  • Raymond A. Dwek, Non-Independent Director (Age 75)
  • Christopher Causey, Independent Director (Age 54)
  • Richard A. Giltner, Independent Director (Age 53)
  • Katherine J. Klein Ph.D., Independent Director (Age 60)
  • Raymond C. Kurzweil J.D., Independent Director (Age 69)

Who owns United Therapeutics Corporation stock?

United Therapeutics Corporation's stock is owned by a number of of institutional and retail investors. Top institutional investors include Schroder Investment Management Group (2.43%), Old Mutual Global Investors UK Ltd. (2.23%), Dimensional Fund Advisors LP (1.85%), Bank of New York Mellon Corp (1.80%), Wells Fargo & Company MN (1.69%) and Skandinaviska Enskilda Banken AB publ (1.56%). Company insiders that own United Therapeutics Corporation stock include Christopher Causey, Christopher Patusky, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Institutional Ownership Trends for United Therapeutics Corporation.

Who sold United Therapeutics Corporation stock? Who is selling United Therapeutics Corporation stock?

United Therapeutics Corporation's stock was sold by a variety of institutional investors in the last quarter, including BNP Paribas Arbitrage SA, Prudential Financial Inc., First Quadrant L P CA, Los Angeles Capital Management & Equity Research Inc., Skandinaviska Enskilda Banken AB publ, New York State Common Retirement Fund, Schroder Investment Management Group and Canada Pension Plan Investment Board. Company insiders that have sold United Therapeutics Corporation company stock in the last year include Christopher Causey, Christopher Patusky, Martine A Rothblatt, Raymond Dwek, Richard Giltner and Tommy G Thompson. View Insider Buying and Selling for United Therapeutics Corporation.

Who bought United Therapeutics Corporation stock? Who is buying United Therapeutics Corporation stock?

United Therapeutics Corporation's stock was bought by a variety of institutional investors in the last quarter, including Old Mutual Global Investors UK Ltd., JPMorgan Chase & Co., APG Asset Management N.V., Dimensional Fund Advisors LP, Russell Investments Group Ltd., First Trust Advisors LP, Robeco Institutional Asset Management B.V. and Shell Asset Management Co.. View Insider Buying and Selling for United Therapeutics Corporation.

How do I buy United Therapeutics Corporation stock?

Shares of United Therapeutics Corporation can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is United Therapeutics Corporation's stock price today?

One share of United Therapeutics Corporation stock can currently be purchased for approximately $125.41.

How big of a company is United Therapeutics Corporation?

United Therapeutics Corporation has a market capitalization of $5.37 billion and generates $1.60 billion in revenue each year. The biotechnology company earns $713.70 million in net income (profit) each year or $11.34 on an earnings per share basis. United Therapeutics Corporation employs 750 workers across the globe.

How can I contact United Therapeutics Corporation?

United Therapeutics Corporation's mailing address is 1040 SPRING ST, SILVER SPRING, MD 20910, United States. The biotechnology company can be reached via phone at +1-301-6089292 or via email at [email protected]


MarketBeat Community Rating for United Therapeutics Corporation (UTHR)

Community Ranking:  2.2 out of 5 (star star)
Outperform Votes:  312 (Vote Outperform)
Underperform Votes:  411 (Vote Underperform)
Total Votes:  723
MarketBeat's community ratings are surveys of what our community members think about United Therapeutics Corporation and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for United Therapeutics Corporation (NASDAQ:UTHR)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 3 Sell Ratings, 6 Hold Ratings, 2 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Hold (Score: 1.91)
Consensus Price Target: $135.50 (8.05% upside)

Consensus Price Target History for United Therapeutics Corporation (NASDAQ:UTHR)

Price Target History for United Therapeutics Corporation (NASDAQ:UTHR)

Analysts' Ratings History for United Therapeutics Corporation (NASDAQ:UTHR)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
10/27/2017Cowen IncReiterated RatingHold$129.00N/AView Rating Details
10/26/2017HC WainwrightReiterated RatingHold$95.00N/AView Rating Details
9/8/2017Oppenheimer Holdings, Inc.Reiterated RatingBuyLowView Rating Details
7/14/2017Jefferies Group LLCReiterated RatingSell$105.00LowView Rating Details
4/27/2017WedbushReiterated RatingOutperform -> Outperform$229.00 -> $213.00LowView Rating Details
4/11/2017J P Morgan Chase & CoSet Price TargetHold$125.00LowView Rating Details
4/3/2017Credit Suisse GroupReiterated RatingUnderperform$120.00HighView Rating Details
2/23/2017Ladenburg Thalmann Financial ServicesDowngradeBuy -> Neutral$145.00N/AView Rating Details
2/23/2017Leerink SwannBoost Price TargetMarket Perform$127.00 -> $148.00N/AView Rating Details
1/19/2017Standpoint ResearchDowngradeBuy -> HoldN/AView Rating Details
11/29/2016Barclays PLCDowngradeEqual Weight -> Underweight$115.00 -> $100.00N/AView Rating Details
8/23/2016ArgusReiterated RatingHoldN/AView Rating Details
4/11/2016Royal Bank Of CanadaReiterated RatingSector Perform$150.00 -> $122.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for United Therapeutics Corporation (NASDAQ:UTHR)

Earnings by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Earnings History by Quarter for United Therapeutics Corporation (NASDAQ UTHR)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/20/2018$3.59N/AView Earnings Details
10/25/2017Q3 2017$4.01$6.27$426.43 million$445.50 millionViewN/AView Earnings Details
7/27/2017Q2 2017$3.61($1.25)$391.53 million$444.60 millionViewN/AView Earnings Details
4/26/2017Q1 2017$3.13$3.89$399.59 million$370.50 millionViewN/AView Earnings Details
2/22/2017Q416$3.61$4.12$415.51 million$409.00 millionViewListenView Earnings Details
10/27/2016Q316$3.38$4.36$400.58 million$408.20 millionViewListenView Earnings Details
7/28/2016Q216$3.22$4.55$395.15 million$412.60 millionViewListenView Earnings Details
4/28/2016Q116$3.21$3.02$395.02 million$369.00 millionViewListenView Earnings Details
2/25/2016Q415$2.70$3.68$388.29 million$404.90 millionViewListenView Earnings Details
10/27/2015Q315$2.35$3.55$363.51 million$386.20 millionViewListenView Earnings Details
7/28/2015Q215$2.31$2.55$360.41 million$347.20 millionViewListenView Earnings Details
4/28/2015Q115$2.14$2.55$353.50 million$327.60 millionViewN/AView Earnings Details
2/24/2015Q414$2.03$3.21$336.22 million$346.40 millionViewN/AView Earnings Details
10/28/2014Q314$1.97$3.91$335.10 million$330.00 millionViewN/AView Earnings Details
7/29/2014Q214$1.75$2.57$308.04 million$322.80 millionViewN/AView Earnings Details
4/29/2014Q114$1.65$1.77$300.14 million$289.40 millionViewN/AView Earnings Details
2/25/2014Q413$1.51$2.88$295.43 million$289.02 millionViewN/AView Earnings Details
10/29/2013Q313$1.59$2.98$279.02 million$302.20 millionViewN/AView Earnings Details
7/25/2013Q2 2013$1.47$1.52$250.17 million$280.60 millionViewN/AView Earnings Details
4/25/2013Q1 2013$1.47$1.19$241.14 million$245.14 millionViewN/AView Earnings Details
2/26/2013Q4 2012$1.25$1.65$233.41 million$243.82 millionViewN/AView Earnings Details
11/1/2012Q312$1.26$2.82$227.63 million$242.50 millionViewN/AView Earnings Details
7/26/2012$1.23$1.34ViewN/AView Earnings Details
4/26/2012$1.00$1.32ViewN/AView Earnings Details
2/14/2012$0.85$0.77ViewN/AView Earnings Details
10/27/2011$0.88$1.32ViewN/AView Earnings Details
7/28/2011$0.49$1.27ViewN/AView Earnings Details
4/28/2011$0.64$1.29ViewN/AView Earnings Details
2/15/2011$0.62$0.15ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for United Therapeutics Corporation (NASDAQ:UTHR)
2017 EPS Consensus Estimate: $14.57
2018 EPS Consensus Estimate: $12.37
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20174$3.08$3.89$3.37
Q2 20174$3.43$4.47$3.81
Q3 20174$3.48$4.06$3.82
Q4 20174$3.08$3.92$3.57
Q1 20182$3.20$3.61$3.41
Q2 20182$3.15$3.47$3.31
Q3 20182$2.44$3.31$2.88
Q4 20182$2.28$3.28$2.78
(Data provided by Zacks Investment Research)

Dividends

Dividend History for United Therapeutics Corporation (NASDAQ:UTHR)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for United Therapeutics Corporation (NASDAQ UTHR)

Insider Ownership Percentage: 7.80%
Insider Trades by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)
Institutional Ownership by Quarter for United Therapeutics Corporation (NASDAQ:UTHR)

Insider Trades by Quarter for United Therapeutics Corporation (NASDAQ UTHR)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/16/2017Martine A RothblattCEOSell7,061$121.12$855,228.32View SEC Filing  
11/9/2017Martine A RothblattCEOSell1,260$121.46$153,039.60View SEC Filing  
11/6/2017Christopher CauseyDirectorSell580$122.00$70,760.00View SEC Filing  
11/2/2017Martine A RothblattCEOSell1,269$118.04$149,792.76View SEC Filing  
10/26/2017Martine A RothblattCEOSell1,263$120.38$152,039.94View SEC Filing  
10/19/2017Martine A RothblattCEOSell1,265$119.38$151,015.70View SEC Filing  
10/12/2017Martine A RothblattCEOSell1,263$120.20$151,812.60View SEC Filing  
10/5/2017Christopher CauseyDirectorSell580$122.00$70,760.00View SEC Filing  
10/5/2017Martine A RothblattCEOSell1,256$122.98$154,462.88View SEC Filing  
9/28/2017Martine A RothblattCEOSell1,265$119.70$151,420.50View SEC Filing  
9/21/2017Martine A RothblattCEOSell1,274$116.07$147,873.18View SEC Filing  
9/14/2017Martine A RothblattCEOSell1,258$122.08$153,576.64View SEC Filing  
9/7/2017Christopher CauseyDirectorSell580$134.48$77,998.40View SEC Filing  
9/7/2017Martine A RothblattCEOSell1,232$133.32$164,250.24View SEC Filing  
8/31/2017Martine A RothblattCEOSell1,235$130.49$161,155.15View SEC Filing  
8/24/2017Martine A RothblattCEOSell1,238$130.65$161,744.70View SEC Filing  
8/17/2017Martine A RothblattCEOSell1,235$131.95$162,958.25View SEC Filing  
8/10/2017Martine A RothblattCEOSell2,176$127.11$276,591.36View SEC Filing  
8/3/2017Martine A RothblattCEOSell1,248$126.41$157,759.68View SEC Filing  
7/27/2017Martine A RothblattCEOSell1,247$126.40$157,620.80View SEC Filing  
7/20/2017Martine A RothblattCEOSell1,236$131.62$162,682.32View SEC Filing  
7/13/2017Martine A RothblattCEOSell1,238$130.44$161,484.72View SEC Filing  
7/6/2017Christopher CauseyDirectorSell590$132.61$78,239.90View SEC Filing  
7/6/2017Martine A RothblattCEOSell1,234$132.29$163,245.86View SEC Filing  
7/5/2017Richard GiltnerDirectorSell3,490$131.12$457,608.80View SEC Filing  
6/29/2017Martine A RothblattCEOSell1,237$130.92$161,948.04View SEC Filing  
6/23/2017Raymond DwekDirectorSell3,490$131.71$459,667.90View SEC Filing  
6/22/2017Martine A RothblattCEOSell1,234$132.32$163,282.88View SEC Filing  
6/15/2017Martine A RothblattCEOSell1,238$130.20$161,187.60View SEC Filing  
6/8/2017Martine A RothblattCEOSell1,240$129.60$160,704.00View SEC Filing  
6/1/2017Martine A RothblattCEOSell1,251$125.02$156,400.02View SEC Filing  
5/25/2017Martine A RothblattCEOSell1,265$119.40$151,041.00View SEC Filing  
5/18/2017Martine A RothblattCEOSell1,261$120.72$152,227.92View SEC Filing  
5/11/2017Martine A RothblattCEOSell1,259$122.00$153,598.00View SEC Filing  
5/4/2017Martine A RothblattCEOSell1,258$122.24$153,777.92View SEC Filing  
4/27/2017Martine A RothblattCEOSell1,262$120.78$152,424.36View SEC Filing  
4/20/2017Martine A RothblattCEOSell1,260$121.14$152,636.40View SEC Filing  
4/13/2017Martine A RothblattCEOSell1,258$122.12$153,626.96View SEC Filing  
4/6/2017Martine A RothblattCEOSell1,257$122.39$153,844.23View SEC Filing  
3/30/2017Martine A RothblattCEOSell1,230$134.56$165,508.80View SEC Filing  
3/23/2017Martine A RothblattCEOSell1,219$139.33$169,843.27View SEC Filing  
3/22/2017Tommy G ThompsonDirectorSell2,000$139.37$278,740.00View SEC Filing  
3/16/2017Martine A RothblattCEOSell1,218$140.16$170,714.88View SEC Filing  
3/9/2017Martine A RothblattCEOSell1,206$146.72$176,944.32View SEC Filing  
3/2/2017Martine A RothblattCEOSell1,203$148.49$178,633.47View SEC Filing  
2/23/2017Martine A RothblattCEOSell1,208$145.16$175,353.28View SEC Filing  
2/16/2017Martine A RothblattCEOSell1,173$167.92$196,970.16View SEC Filing  
1/12/2017Christopher PatuskyDirectorSell5,000$141.99$709,950.00View SEC Filing  
1/12/2017Martine A RothblattCEOSell1,214$142.37$172,837.18View SEC Filing  
1/5/2017Martine A RothblattCEOSell1,208$145.73$176,041.84View SEC Filing  
12/29/2016Martine A RothblattCEOSell1,211$143.63$173,935.93View SEC Filing  
12/22/2016Martine A RothblattCEOSell1,218$140.23$170,800.14View SEC Filing  
12/15/2016Martine A RothblattCEOSell1,212$143.11$173,449.32View SEC Filing  
12/8/2016Martine A RothblattCEOSell1,236$131.78$162,880.08View SEC Filing  
12/6/2016Richard GiltnerDirectorSell5,000$133.37$666,850.00View SEC Filing  
12/1/2016Martine A RothblattCEOSell1,246$126.86$158,067.56View SEC Filing  
11/25/2016Martine A RothblattCEOSell1,233$132.81$163,754.73View SEC Filing  
11/17/2016Martine A RothblattCEOSell1,232$132.94$163,782.08View SEC Filing  
11/10/2016Christopher PatuskyDirectorSell5,000$131.42$657,100.00View SEC Filing  
11/10/2016Martine A RothblattCEOSell1,240$129.82$160,976.80View SEC Filing  
11/3/2016Martine A RothblattCEOSell1,272$116.94$148,747.68View SEC Filing  
10/27/2016Martine A RothblattCEOSell1,272$117.06$148,900.32View SEC Filing  
10/20/2016Martine A RothblattCEOSell1,282$113.30$145,250.60View SEC Filing  
10/13/2016Martine A RothblattCEOSell1,269$117.99$149,729.31View SEC Filing  
10/6/2016Martine A RothblattCEOSell1,260$121.17$152,674.20View SEC Filing  
9/29/2016Martine A RothblattCEOSell1,272$116.94$148,747.68View SEC Filing  
9/26/2016Tommy G ThompsonDirectorSell1,291$125.57$162,110.87View SEC Filing  
9/22/2016Martine A RothblattCEOSell1,249$125.87$157,211.63View SEC Filing  
9/15/2016Martine A RothblattCEOSell1,258$122.34$153,903.72View SEC Filing  
9/8/2016Martine A RothblattCEOSell1,254$123.44$154,793.76View SEC Filing  
9/1/2016Christopher PatuskyDirectorSell5,000$122.73$613,650.00View SEC Filing  
9/1/2016Martine A RothblattCEOSell1,257$122.81$154,372.17View SEC Filing  
8/25/2016Martine A RothblattCEOSell1,250$125.29$156,612.50View SEC Filing  
8/18/2016Martine A RothblattCEOSell1,249$125.88$157,224.12View SEC Filing  
8/11/2016Martine A RothblattCEOSell1,253$124.09$155,484.77View SEC Filing  
8/4/2016Martine A RothblattCEOSell1,249$125.78$157,099.22View SEC Filing  
7/28/2016Martine A RothblattCEOSell1,271$117.05$148,770.55View SEC Filing  
7/21/2016Martine A RothblattCEOSell1,284$112.77$144,796.68View SEC Filing  
7/14/2016Martine A RothblattCEOSell1,292$110.05$142,184.60View SEC Filing  
7/7/2016Martine A RothblattCEOSell1,293$109.87$142,061.91View SEC Filing  
6/30/2016Martine A RothblattCEOSell1,308$105.10$137,470.80View SEC Filing  
6/23/2016Martine A RothblattCEOSell1,312$104.07$136,539.84View SEC Filing  
6/16/2016Martine A RothblattCEOSell1,308$105.18$137,575.44View SEC Filing  
6/9/2016Martine A RothblattCEOSell1,277$114.99$146,842.23View SEC Filing  
6/8/2016Tommy G ThompsonDirectorSell2,000$115.62$231,240.00View SEC Filing  
6/2/2016Martine A RothblattCEOSell1,261$120.79$152,316.19View SEC Filing  
6/2/2016Raymond DwekDirectorSell3,000$118.82$356,460.00View SEC Filing  
5/26/2016Martine A RothblattCEOSell5,547$117.57$652,160.79View SEC Filing  
5/19/2016Martine A RothblattCEOSell5,546$110.75$614,219.50View SEC Filing  
5/12/2016Martine A RothblattCEOSell5,547$109.02$604,733.94View SEC Filing  
5/12/2016Raymond DwekDirectorSell3,000$110.00$330,000.00View SEC Filing  
5/5/2016Martine A RothblattCEOSell5,546$107.79$597,803.34View SEC Filing  
4/28/2016Martine A RothblattCEOSell5,547$106.81$592,475.07View SEC Filing  
4/21/2016Martine A RothblattCEOSell5,546$115.74$641,894.04View SEC Filing  
4/14/2016Martine A RothblattCEOSell5,547$114.32$634,133.04View SEC Filing  
4/7/2016Martine A RothblattCEOSell5,546$113.31$628,417.26View SEC Filing  
3/24/2016Martine A RothblattCEOSell5,546$110.80$614,496.80View SEC Filing  
3/17/2016Martine A RothblattCEOSell5,547$118.22$655,766.34View SEC Filing  
3/10/2016Martine A RothblattCEOSell5,546$123.41$684,431.86View SEC Filing  
3/3/2016Martine A RothblattCEOSell5,547$126.78$703,248.66View SEC Filing  
2/25/2016Martine A RothblattCEOSell5,546$122.45$679,107.70View SEC Filing  
2/18/2016Martine A RothblattCEOSell5,547$128.26$711,458.22View SEC Filing  
2/11/2016Martine A. RothblattCEOSell5,546$120.47$668,126.62View SEC Filing  
2/4/2016Martine A. RothblattCEOSell5,547$122.13$677,455.11View SEC Filing  
2/4/2016Raymond DwekDirectorSell3,000$122.66$367,980.00View SEC Filing  
1/28/2016Martine A. RothblattCEOSell5,546$124.00$687,704.00View SEC Filing  
1/21/2016Martine A. RothblattCEOSell5,547$127.00$704,469.00View SEC Filing  
1/14/2016Martine A. RothblattCEOSell5,546$135.94$753,923.24View SEC Filing  
1/7/2016Martine A. RothblattCEOSell5,547$145.84$808,974.48View SEC Filing  
1/7/2016Raymond DwekDirectorSell3,000$143.75$431,250.00View SEC Filing  
12/24/2015Martine A. RothblattCEOSell5,546$159.58$885,030.68View SEC Filing  
12/17/2015Martine A. RothblattCEOSell5,546$158.49$878,985.54View SEC Filing  
12/10/2015Martine A. RothblattCEOSell5,546$154.49$856,801.54View SEC Filing  
12/3/2015Martine A. RothblattCEOSell5,546$154.49$856,801.54View SEC Filing  
12/3/2015Raymond DwekDirectorSell3,000$157.22$471,660.00View SEC Filing  
11/27/2015Martine A. RothblattCEOSell5,561$153.81$855,337.41View SEC Filing  
11/19/2015Martine A. RothblattCEOSell9,661$148.56$1,435,238.16View SEC Filing  
11/12/2015Martine A. RothblattCEOSell4,115$147.72$607,867.80View SEC Filing  
11/5/2015Martine A. RothblattCEOSell4,115$149.16$613,793.40View SEC Filing  
11/5/2015Raymond DwekDirectorSell3,000$149.63$448,890.00View SEC Filing  
11/3/2015Richard GiltnerDirectorSell7,500$153.22$1,149,150.00View SEC Filing  
10/29/2015Martine A. RothblattCEOSell9,662$141.89$1,370,941.18View SEC Filing  
10/28/2015Martine A. RothblattCEOSell2,211$136.58$301,978.38View SEC Filing  
10/26/2015Martine A. RothblattCEOSell2,592$127.13$329,520.96View SEC Filing  
10/22/2015Martine A. RothblattCEOSell9,662$122.40$1,182,628.80View SEC Filing  
10/21/2015Martine A. RothblattCEOSell2,211$123.63$273,345.93View SEC Filing  
10/19/2015Martine A. RothblattCEOSell2,592$126.71$328,432.32View SEC Filing  
10/15/2015Martine A. RothblattCEOSell9,662$126.22$1,219,537.64View SEC Filing  
10/14/2015Martine A. RothblattCEOSell2,211$123.53$273,124.83View SEC Filing  
10/12/2015Martine A. RothblattCEOSell2,592$123.51$320,137.92View SEC Filing  
10/8/2015Martine A. RothblattCEOSell9,662$122.48$1,183,401.76View SEC Filing  
10/7/2015Martine A. RothblattCEOSell2,211$120.88$267,265.68View SEC Filing  
10/5/2015Martine A. RothblattCEOSell2,592$126.88$328,872.96View SEC Filing  
10/1/2015Martine A. RothblattCEOSell6,326$131.11$829,401.86View SEC Filing  
10/1/2015Paul A. MahonEVPSell6,000$129.38$776,280.00View SEC Filing  
10/1/2015Raymond DwekDirectorSell3,000$131.32$393,960.00View SEC Filing  
9/29/2015Martine A. RothblattCEOSell2,592$134.25$347,976.00View SEC Filing  
9/29/2015Tommy G. ThompsonDirectorSell5,000$139.19$695,950.00View SEC Filing  
9/24/2015Martine A. RothblattCEOSell9,662$139.26$1,345,530.12View SEC Filing  
9/23/2015Martine A. RothblattCEOSell2,211$142.05$314,072.55View SEC Filing  
9/21/2015Martine A. RothblattCEOSell2,592$150.81$390,899.52View SEC Filing  
9/17/2015Martine A. RothblattCEOSell9,662$152.02$1,468,817.24View SEC Filing  
9/16/2015Martine A. RothblattCEOSell2,211$151.93$335,917.23View SEC Filing  
9/14/2015Martine A. RothblattCEOSell2,592$153.08$396,783.36View SEC Filing  
9/10/2015Martine A. RothblattCEOSell4,115$152.95$629,389.25View SEC Filing  
9/9/2015Martine A. RothblattCEOSell2,211$152.77$337,774.47View SEC Filing  
9/8/2015Martine A. RothblattCEOSell2,592$152.80$396,057.60View SEC Filing  
9/3/2015Martine A. RothblattCEOSell9,662$153.67$1,484,759.54View SEC Filing  
9/3/2015Raymond DwekDirectorSell3,000$155.54$466,620.00View SEC Filing  
9/2/2015Martine A. RothblattCEOSell2,211$151.12$334,126.32View SEC Filing  
8/31/2015Martine A. RothblattCEOSell2,592$153.50$397,872.00View SEC Filing  
8/27/2015Martine A. RothblattCEOSell9,662$160.37$1,549,494.94View SEC Filing  
8/26/2015Martine A. RothblattCEOSell2,211$155.47$343,744.17View SEC Filing  
8/24/2015Martine A. RothblattCEOSell2,592$155.36$402,693.12View SEC Filing  
8/20/2015Martine A. RothblattCEOSell9,662$166.58$1,609,495.96View SEC Filing  
8/19/2015Martine A. RothblattCEOSell2,211$167.13$369,524.43View SEC Filing  
8/17/2015Martine A RothblattCEOSell2,592$166.61$431,853.12View SEC Filing  
8/13/2015Martine A RothblattCEOSell9,662$165.05$1,594,713.10View SEC Filing  
7/27/2015Martine A RothblattCEOSell2,592$166.38$431,256.96View SEC Filing  
7/23/2015Martine A RothblattCEOSell4,115$176.38$725,803.70View SEC Filing  
7/22/2015Martine A RothblattCEOSell2,211$174.55$385,930.05View SEC Filing  
7/20/2015Martine A RothblattCEOSell2,592$177.92$461,168.64View SEC Filing  
7/16/2015Martine A RothblattCEOSell9,662$175.51$1,695,777.62View SEC Filing  
7/15/2015Martine A RothblattCEOSell2,211$176.77$390,838.47View SEC Filing  
7/13/2015Martine A RothblattCEOSell2,592$172.42$446,912.64View SEC Filing  
7/9/2015Martine A RothblattCEOSell9,662$168.04$1,623,602.48View SEC Filing  
7/8/2015Martine A RothblattCEOSell2,211$167.13$369,524.43View SEC Filing  
7/6/2015Martine A RothblattCEOSell2,592$170.66$442,350.72View SEC Filing  
7/2/2015Martine A RothblattCEOSell6,326$170.69$1,079,784.94View SEC Filing  
7/2/2015Raymond DwekDirectorSell3,000$171.59$514,770.00View SEC Filing  
6/29/2015Martine A RothblattCEOSell2,592$172.86$448,053.12View SEC Filing  
6/25/2015Martine A RothblattCEOSell9,662$176.91$1,709,304.42View SEC Filing  
6/24/2015Martine A RothblattCEOSell2,211$179.68$397,272.48View SEC Filing  
6/22/2015Martine A RothblattCEOSell2,592$188.64$488,954.88View SEC Filing  
6/18/2015Louis W SullivanDirectorSell15,000$185.60$2,784,000.00View SEC Filing  
6/18/2015Martine A RothblattCEOSell9,662$185.72$1,794,426.64View SEC Filing  
6/17/2015Martine A RothblattCEOSell2,211$185.25$409,587.75View SEC Filing  
6/15/2015Martine A RothblattCEOSell2,592$185.15$479,908.80View SEC Filing  
6/11/2015Martine A RothblattCEOSell9,662$183.76$1,775,489.12View SEC Filing  
6/10/2015Martine A RothblattCEOSell2,211$180.87$399,903.57View SEC Filing  
6/8/2015Martine A RothblattCEOSell2,592$181.34$470,033.28View SEC Filing  
6/4/2015Martine A RothblattCEOSell9,662$181.94$1,757,904.28View SEC Filing  
6/4/2015Raymond DwekDirectorSell3,000$181.36$544,080.00View SEC Filing  
6/3/2015Martine A RothblattCEOSell2,211$184.49$407,907.39View SEC Filing  
6/1/2015Martine A RothblattCEOSell2,592$182.66$473,454.72View SEC Filing  
5/28/2015Martine A RothblattCEOSell9,662$180.88$1,747,662.56View SEC Filing  
5/27/2015Martine A RothblattCEOSell2,211$184.39$407,686.29View SEC Filing  
5/26/2015Martine A RothblattCEOSell2,592$182.64$473,402.88View SEC Filing  
5/21/2015Martine A RothblattCEOSell9,662$182.44$1,762,735.28View SEC Filing  
5/21/2015Tommy G ThompsonDirectorSell1,500$182.04$273,060.00View SEC Filing  
5/20/2015Martine A RothblattCEOSell2,211$182.80$404,170.80View SEC Filing  
5/18/2015Martine A RothblattCEOSell2,592$177.79$460,831.68View SEC Filing  
5/14/2015Martine A RothblattCEOSell9,662$174.07$1,681,864.34View SEC Filing  
5/13/2015Martine A RothblattCEOSell2,211$175.41$387,831.51View SEC Filing  
5/11/2015Martine A RothblattCEOSell2,592$179.55$465,393.60View SEC Filing  
5/7/2015Christopher CauseyDirectorSell1,500$167.94$251,910.00View SEC Filing  
5/7/2015Martine A RothblattCEOSell9,662$169.86$1,641,187.32View SEC Filing  
5/6/2015Martine A RothblattCEOSell2,211$169.22$374,145.42View SEC Filing  
5/4/2015Martine A RothblattCEOSell2,592$169.81$440,147.52View SEC Filing  
5/1/2015Raymond DwekDirectorSell3,000$159.58$478,740.00View SEC Filing  
4/30/2015Martine A RothblattCEOSell9,662$162.36$1,568,722.32View SEC Filing  
4/29/2015Martine A RothblattCEOSell2,211$164.29$363,245.19View SEC Filing  
4/28/2015Roger JeffsCEOSell5,000$163.31$816,550.00View SEC Filing  
4/27/2015Martine A RothblattCEOSell2,592$177.62$460,391.04View SEC Filing  
4/23/2015Martine A RothblattCEOSell9,662$187.35$1,810,175.70View SEC Filing  
4/22/2015Martine A RothblattCEOSell2,211$187.49$414,540.39View SEC Filing  
4/21/2015Roger JeffsCEOSell10,000$187.86$1,878,600.00View SEC Filing  
4/20/2015Martine A RothblattCEOSell2,592$184.86$479,157.12View SEC Filing  
4/16/2015Martine A RothblattCEOSell11,873$187.01$2,220,369.73View SEC Filing  
4/16/2015Paul A MahonEVPSell6,000$187.91$1,127,460.00View SEC Filing  
4/14/2015David ZaccardelliCOOSell3,250$185.82$603,915.00View SEC Filing  
4/14/2015Roger JeffsCEOSell10,000$185.82$1,858,200.00View SEC Filing  
4/13/2015Martine A RothblattCEOSell2,592$187.86$486,933.12View SEC Filing  
4/9/2015David ZaccardelliCOOSell4,000$184.84$739,360.00View SEC Filing  
4/9/2015Martine A RothblattCEOSell9,662$183.09$1,769,015.58View SEC Filing  
4/8/2015Martine A RothblattCEOSell2,211$181.91$402,203.01View SEC Filing  
4/7/2015David ZaccardelliCOOSell4,000$179.34$717,360.00View SEC Filing  
4/7/2015Roger JeffsCEOSell10,000$179.34$1,793,400.00View SEC Filing  
4/6/2015Martine A RothblattCEOSell2,592$176.20$456,710.40View SEC Filing  
4/2/2015David ZaccardelliCOOSell4,000$174.73$698,920.00View SEC Filing  
4/2/2015Martine A RothblattCEOSell11,873$173.43$2,059,134.39View SEC Filing  
4/2/2015Paul A MahonEVPSell6,000$174.73$1,048,380.00View SEC Filing  
4/2/2015Raymond DwekDirectorSell3,000$175.49$526,470.00View SEC Filing  
3/30/2015Martine A RothblattCEOSell2,592$177.22$459,354.24View SEC Filing  
3/26/2015David ZaccardelliCOOSell4,000$167.52$670,080.00View SEC Filing  
3/26/2015Martine A RothblattCEOSell9,662$167.03$1,613,843.86View SEC Filing  
3/25/2015Martine A RothblattCEOSell2,211$173.67$383,984.37View SEC Filing  
3/24/2015David ZaccardelliCOOSell4,500$179.51$807,795.00View SEC Filing  
3/23/2015Martine A RothblattCEOSell2,592$177.76$460,753.92View SEC Filing  
3/19/2015Paul A MahonEVPSell6,000$175.82$1,054,920.00View SEC Filing  
3/18/2015Martine A RothblattCEOSell2,211$174.64$386,129.04View SEC Filing  
3/17/2015David ZaccardelliCOOSell4,000$177.34$709,360.00View SEC Filing  
3/16/2015Martine A RothblattCEOSell2,592$170.97$443,154.24View SEC Filing  
3/12/2015Martine A RothblattCEOSell11,873$162.94$1,934,586.62View SEC Filing  
3/10/2015Roger JeffsCEOSell18,750$143.68$2,694,000.00View SEC Filing  
3/9/2015Martine A RothblattCEOSell2,592$160.51$416,041.92View SEC Filing  
3/5/2015Martine A RothblattCEOSell9,662$159.75$1,543,504.50View SEC Filing  
3/5/2015Raymond DwekDirectorSell3,000$157.59$472,770.00View SEC Filing  
3/4/2015Martine A RothblattCEOSell2,211$157.63$348,519.93View SEC Filing  
3/3/2015Roger JeffsCEOSell10,000$157.74$1,577,400.00View SEC Filing  
3/2/2015Martine A RothblattCEOSell2,592$155.32$402,589.44View SEC Filing  
2/27/2015Ray KurzweilDirectorSell15,000$155.05$2,325,750.00View SEC Filing  
2/26/2015Martine A RothblattCEOSell9,662$155.23$1,499,832.26View SEC Filing  
2/25/2015Martine A RothblattCEOSell2,211$159.35$352,322.85View SEC Filing  
2/24/2015David ZaccardelliCOOSell1,458$155.16$226,223.28View SEC Filing  
2/24/2015Roger JeffsCEOSell10,000$155.16$1,551,600.00View SEC Filing  
2/23/2015Martine A RothblattCEOSell2,592$156.08$404,559.36View SEC Filing  
2/19/2015John Maxim FerrariCFOSell10,000$155.72$1,557,200.00View SEC Filing  
2/19/2015Martine A RothblattCEOSell9,662$155.99$1,507,175.38View SEC Filing  
2/19/2015Paul A MahonEVPSell6,000$155.72$934,320.00View SEC Filing  
2/17/2015David ZaccardelliCOOSell4,000$155.14$620,560.00View SEC Filing  
2/17/2015Martine A RothblattCEOSell2,592$152.28$394,709.76View SEC Filing  
2/12/2015Martine A RothblattCEOSell9,662$146.01$1,410,748.62View SEC Filing  
2/11/2015Martine A RothblattCEOSell2,211$147.29$325,658.19View SEC Filing  
2/10/2015David ZaccardelliCOOSell4,000$146.68$586,720.00View SEC Filing  
2/10/2015Roger JeffsCEOSell10,000$146.68$1,466,800.00View SEC Filing  
2/9/2015Martine A RothblattCEOSell2,592$143.32$371,485.44View SEC Filing  
2/5/2015John Maxim FerrariCFOSell10,000$141.92$1,419,200.00View SEC Filing  
2/5/2015Martine A RothblattCEOSell11,773$141.07$1,660,817.11View SEC Filing  
2/5/2015Paul A MahonEVPSell6,000$141.92$851,520.00View SEC Filing  
2/5/2015Raymond DwekDirectorSell3,000$140.41$421,230.00View SEC Filing  
2/3/2015David ZaccardelliCOOSell4,000$141.99$567,960.00View SEC Filing  
2/3/2015Roger JeffsCEOSell10,000$141.99$1,419,900.00View SEC Filing  
1/29/2015Martine A RothblattCEOSell9,662$143.29$1,384,467.98View SEC Filing  
1/28/2015Martine A RothblattCEOSell2,211$145.49$321,678.39View SEC Filing  
1/27/2015David ZaccardelliCOOSell4,000$147.19$588,760.00View SEC Filing  
1/27/2015Roger JeffsCEOSell10,000$147.19$1,471,900.00View SEC Filing  
1/26/2015Martine A RothblattCEOSell2,592$145.89$378,146.88View SEC Filing  
1/22/2015Martine A RothblattCEOSell11,873$146.76$1,742,481.48View SEC Filing  
1/20/2015David ZaccardelliCOOSell4,000$146.48$585,920.00View SEC Filing  
1/20/2015Martine A RothblattCEOSell2,592$145.06$375,995.52View SEC Filing  
1/15/2015John Maxim FerrariCFOSell22,500$137.84$3,101,400.00View SEC Filing  
1/15/2015Martine A RothblattCEOSell9,662$137.51$1,328,621.62View SEC Filing  
1/15/2015Paul A MahonEVPSell6,000$137.84$827,040.00View SEC Filing  
1/14/2015Martine A RothblattCEOSell2,211$135.18$298,882.98View SEC Filing  
1/13/2015David ZaccardelliCOOSell3,000$134.71$404,130.00View SEC Filing  
1/13/2015Roger JeffsCEOSell10,000$134.71$1,347,100.00View SEC Filing  
1/12/2015Martine A RothblattCEOSell2,592$132.00$342,144.00View SEC Filing  
1/8/2015Christopher PatuskyDirectorSell5,000$128.13$640,650.00View SEC Filing  
1/8/2015Martine A RothblattCEOSell9,662$128.31$1,239,731.22View SEC Filing  
1/7/2015Martine A RothblattCEOSell2,211$126.04$278,674.44View SEC Filing  
1/6/2015David ZaccardelliCOOSell3,000$124.93$374,790.00View SEC Filing  
1/6/2015Roger JeffsCEOSell7,500$124.93$936,975.00View SEC Filing  
1/5/2015Martine A RothblattCEOSell2,592$126.88$328,872.96View SEC Filing  
1/2/2015Christopher CauseyDirectorSell3,000$129.25$387,750.00View SEC Filing  
1/2/2015Martine A RothblattCEOSell9,662$126.53$1,222,532.86View SEC Filing  
1/2/2015Paul A MahonEVPSell6,000$127.73$766,380.00View SEC Filing  
12/31/2014Martine A RothblattCEOSell2,211$131.35$290,414.85View SEC Filing  
12/30/2014Roger JeffsCEOSell10,000$130.80$1,308,000.00View SEC Filing  
12/29/2014Martine A RothblattCEOSell2,592$131.75$341,496.00View SEC Filing  
12/26/2014Martine A RothblattCEOSell9,662$131.85$1,273,934.70View SEC Filing  
12/24/2014Martine A RothblattCEOSell2,211$130.35$288,203.85View SEC Filing  
12/23/2014Roger JeffsCOOSell10,000$127.82$1,278,200.00View SEC Filing  
12/22/2014Martine A RothblattCEOSell2,592$133.45$345,902.40View SEC Filing  
12/19/2014Christopher CauseyDirectorSell1,500$131.47$197,205.00View SEC Filing  
12/18/2014John Maxim FerrariCFOSell10,000$131.11$1,311,100.00View SEC Filing  
12/18/2014Martine A RothblattCEOSell9,662$129.06$1,246,977.72View SEC Filing  
12/18/2014Paul A MahonEVPSell10,750$130.03$1,397,822.50View SEC Filing  
12/17/2014Martine A RothblattCEOSell2,211$126.04$278,674.44View SEC Filing  
12/15/2014Martine A RothblattCEOSell2,592$129.75$336,312.00View SEC Filing  
12/11/2014Martine A RothblattCEOSell9,662$130.98$1,265,528.76View SEC Filing  
12/10/2014Martine A RothblattCEOSell2,211$132.77$293,554.47View SEC Filing  
12/9/2014Roger JeffsCOOSell10,000$134.80$1,348,000.00View SEC Filing  
12/8/2014Martine A RothblattCEOSell2,592$132.34$343,025.28View SEC Filing  
12/4/2014John Maxim FerrariCFOSell10,000$129.05$1,290,500.00View SEC Filing  
12/4/2014Martine A RothblattCEOSell11,873$131.32$1,559,162.36View SEC Filing  
12/4/2014Paul A MahonEVPSell11,000$129.92$1,429,120.00View SEC Filing  
12/4/2014Raymond DwekDirectorSell3,000$131.58$394,740.00View SEC Filing  
12/2/2014Roger JeffsCOOSell10,000$133.63$1,336,300.00View SEC Filing  
12/1/2014Martine A RothblattCEOSell2,592$132.92$344,528.64View SEC Filing  
11/28/2014Martine A RothblattCEOSell11,873$132.77$1,576,378.21View SEC Filing  
11/25/2014Roger JeffsCOOSell10,000$131.30$1,313,000.00View SEC Filing  
11/24/2014Martine A RothblattCEOSell2,592$130.72$338,826.24View SEC Filing  
11/21/2014Roger JeffsCOOSell10,000$130.15$1,301,500.00View SEC Filing  
11/20/2014Christopher CauseyDirectorSell1,500$127.20$190,800.00View SEC Filing  
11/20/2014John Maxim FerrariCFOSell10,000$129.22$1,292,200.00View SEC Filing  
11/20/2014Martine A RothblattCEOSell9,662$128.86$1,245,045.32View SEC Filing  
11/20/2014Paul A MahonEVPSell11,000$129.02$1,419,220.00View SEC Filing  
11/19/2014Martine A RothblattCEOSell2,211$128.69$284,533.59View SEC Filing  
11/18/2014Roger JeffsCOOSell10,000$128.21$1,282,100.00View SEC Filing  
11/17/2014Martine A RothblattCEOSell2,592$125.65$325,684.80View SEC Filing  
11/13/2014Martine A RothblattCEOSell9,662$124.79$1,205,720.98View SEC Filing  
11/12/2014Martine A RothblattCEOSell2,211$122.88$271,687.68View SEC Filing  
11/10/2014Martine A RothblattCEOSell2,592$125.14$324,362.88View SEC Filing  
11/7/2014Christopher PatuskyDirectorSell5,000$124.49$622,450.00View SEC Filing  
11/7/2014Roger JeffsCOOSell10,000$124.46$1,244,600.00View SEC Filing  
11/6/2014Christopher CauseyDirectorSell1,500$122.89$184,335.00View SEC Filing  
11/6/2014Martine A RothblattCEOSell4,115$125.33$515,732.95View SEC Filing  
11/6/2014Paul A MahonEVPSell5,000$125.02$625,100.00View SEC Filing  
11/5/2014Martine A RothblattCEOSell2,211$124.31$274,849.41View SEC Filing  
11/3/2014Martine A RothblattCEOSell2,592$127.49$330,454.08View SEC Filing  
10/30/2014Martine A RothblattCEOSell9,662$130.42$1,260,118.04View SEC Filing  
10/29/2014Martine A RothblattCEOSell2,211$131.10$289,862.10View SEC Filing  
10/27/2014Martine A RothblattCEOSell2,592$132.16$342,558.72View SEC Filing  
10/23/2014Martine A RothblattCEOSell11,873$129.97$1,543,133.81View SEC Filing  
10/23/2014Paul A MahonEVPSell11,000$127.04$1,397,440.00View SEC Filing  
10/13/2014Martine A RothblattCEOSell2,592$124.31$322,211.52View SEC Filing  
10/9/2014Martine A RothblattCEOSell9,662$129.97$1,255,770.14View SEC Filing  
10/9/2014Paul A MahonEVPSell5,000$130.59$652,950.00View SEC Filing  
10/8/2014Martine A RothblattCEOSell2,211$131.50$290,746.50View SEC Filing  
10/7/2014Roger JeffsCOOSell35,000$130.14$4,554,900.00View SEC Filing  
10/6/2014Martine A RothblattCEOSell2,592$129.32$335,197.44View SEC Filing  
10/3/2014Roger JeffsCOOSell10,000$129.79$1,297,900.00View SEC Filing  
10/2/2014Christopher CauseyDirectorSell1,500$130.65$195,975.00View SEC Filing  
10/2/2014John Maxim FerrariCFOSell10,000$129.46$1,294,600.00View SEC Filing  
10/2/2014Martine A RothblattCEOSell9,662$127.72$1,234,030.64View SEC Filing  
10/2/2014Paul A MahonEVPSell6,000$129.46$776,760.00View SEC Filing  
10/1/2014Martine A RothblattCEOSell2,211$127.40$281,681.40View SEC Filing  
9/30/2014Roger JeffsCOOSell20,000$128.65$2,573,000.00View SEC Filing  
9/25/2014Martine A RothblattCEOSell5,547$134.26$744,740.22View SEC Filing  
9/25/2014Paul A MahonEVPSell5,000$133.77$668,850.00View SEC Filing  
9/25/2014Richard GiltnerDirectorSell20,000$134.94$2,698,800.00View SEC Filing  
9/23/2014Roger JeffsCOOSell50,000$131.02$6,551,000.00View SEC Filing  
9/19/2014Roger JeffsCOOSell10,000$129.60$1,296,000.00View SEC Filing  
9/18/2014John Maxim FerrariCFOSell10,000$130.93$1,309,300.00View SEC Filing  
9/18/2014Martine A RothblattCEOSell9,662$127.35$1,230,455.70View SEC Filing  
9/18/2014Paul A MahonEVPSell6,000$130.93$785,580.00View SEC Filing  
9/17/2014Roger JeffsCOOSell20,000$127.01$2,540,200.00View SEC Filing  
9/15/2014Martine A RothblattCEOSell50,000$124.52$6,226,000.00View SEC Filing  
9/11/2014Martine A RothblattCEOSell9,662$120.79$1,167,072.98View SEC Filing  
9/11/2014Paul A MahonEVPSell5,000$120.70$603,500.00View SEC Filing  
9/10/2014Martine A RothblattCEOSell50,000$120.01$6,000,500.00View SEC Filing  
9/10/2014Richard GiltnerDirectorSell20,000$119.95$2,399,000.00View SEC Filing  
9/5/2014Roger JeffsCOOSell10,000$111.29$1,112,900.00View SEC Filing  
9/4/2014John Maxim FerrariCFOSell10,000$112.38$1,123,800.00View SEC Filing  
9/4/2014Martine A RothblattCEOSell9,662$112.87$1,090,549.94View SEC Filing  
9/4/2014Paul A MahonEVPSell6,000$112.38$674,280.00View SEC Filing  
9/4/2014Raymond DwekDirectorSell3,000$113.40$340,200.00View SEC Filing  
8/28/2014Martine A RothblattCEOSell7,014$92.46$648,514.44View SEC Filing  
8/28/2014Paul A MahonEVPSell5,000$92.07$460,350.00View SEC Filing  
8/21/2014John Maxim FerrariCFOSell10,000$93.75$937,500.00View SEC Filing  
8/21/2014Martine A RothblattCEOSell9,640$93.13$897,773.20View SEC Filing  
8/15/2014Christopher CauseyDirectorSell1,500$91.14$136,710.00View SEC Filing  
8/14/2014Martine A RothblattCEOSell4,115$88.39$363,724.85View SEC Filing  
8/14/2014Paul A MahonEVPSell10,000$88.41$884,100.00View SEC Filing  
8/7/2014Christopher PatuskyDirectorSell5,000$88.23$441,150.00View SEC Filing  
8/7/2014John Maxim FerrariCFOSell10,000$86.44$864,400.00View SEC Filing  
8/7/2014Martine A RothblattCEOSell4,115$88.40$363,766.00View SEC Filing  
8/1/2014Raymond DwekDirectorSell3,000$89.52$268,560.00View SEC Filing  
8/1/2014Roger JeffsCOOSell10,000$89.88$898,800.00View SEC Filing  
7/31/2014Martine A RothblattCEOSell3,933$90.95$357,706.35View SEC Filing  
7/29/2014Roger JeffsCOOSell50,000$96.25$4,812,500.00View SEC Filing  
7/25/2014Roger JeffsCOOSell10,000$91.54$915,400.00View SEC Filing  
7/24/2014Martine A RothblattCEOSell9,228$93.15$859,588.20View SEC Filing  
7/17/2014John Maxim FerrariCFOSell10,000$89.74$897,400.00View SEC Filing  
7/17/2014Martine A RothblattCEOSell3,833$90.87$348,304.71View SEC Filing  
7/11/2014Roger JeffsCOOSell10,000$93.06$930,600.00View SEC Filing  
7/10/2014Martine A RothblattCEOSell9,187$92.33$848,235.71View SEC Filing  
7/3/2014Christopher CauseyDirectorSell1,500$91.62$137,430.00View SEC Filing  
7/3/2014John Maxim FerrariCFOSell10,000$90.58$905,800.00View SEC Filing  
7/3/2014Martine A RothblattCEOSell3,833$91.37$350,221.21View SEC Filing  
6/26/2014Martine A RothblattCEOSell3,833$87.23$334,352.59View SEC Filing  
6/20/2014Roger JeffsCOOSell10,000$87.00$870,000.00View SEC Filing  
6/19/2014John Maxim FerrariCFOSell10,000$87.02$870,200.00View SEC Filing  
6/19/2014Martine A RothblattCEOSell3,833$85.68$328,411.44View SEC Filing  
6/19/2014Paul A MahonEVPSell2,000$85.67$171,340.00View SEC Filing  
6/12/2014Martine A RothblattCEOSell9,066$98.22$890,462.52View SEC Filing  
6/10/2014Roger JeffsCOOSell10,000$96.29$962,900.00View SEC Filing  
6/9/2014Roger JeffsCOOSell10,000$96.32$963,200.00View SEC Filing  
6/5/2014Christopher CauseyDirectorSell1,500$96.48$144,720.00View SEC Filing  
6/5/2014Martine A RothblattCEOSell9,066$96.46$874,506.36View SEC Filing  
6/5/2014Paul A MahonEVPSell6,000$96.50$579,000.00View SEC Filing  
6/3/2014Roger JeffsCOOSell10,000$95.00$950,000.00View SEC Filing  
5/29/2014Martine A RothblattCEOSell9,066$95.27$863,717.82View SEC Filing  
5/27/2014Roger JeffsCOOSell10,000$99.14$991,400.00View SEC Filing  
5/22/2014Louis SullivanDirectorSell30,000$101.46$3,043,800.00View SEC Filing  
5/22/2014Martine RothblattCEOSell9,066$101.35$918,839.10View SEC Filing  
5/20/2014Roger JeffsCOOSell10,000$99.91$999,100.00View SEC Filing  
5/16/2014Roger JeffsCOOSell10,000$100.00$1,000,000.00View SEC Filing  
5/15/2014John Maxim FerrariCFOSell10,000$101.49$1,014,900.00View SEC Filing  
5/15/2014Martine RothblattCEOSell9,066$100.88$914,578.08View SEC Filing  
5/15/2014Paul MahonEVPSell6,000$100.86$605,160.00View SEC Filing  
5/13/2014Roger JeffsCOOSell10,000$105.53$1,055,300.00View SEC Filing  
5/8/2014Christopher PatuskyDirectorSell5,000$107.17$535,850.00View SEC Filing  
5/8/2014Martine RothblattCEOSell9,066$107.83$977,586.78View SEC Filing  
5/6/2014Roger JeffsCOOSell10,000$106.50$1,065,000.00View SEC Filing  
5/2/2014Roger JeffsCOOSell10,000$102.00$1,020,000.00View SEC Filing  
5/1/2014Christopher CauseyDirectorSell1,500$99.30$148,950.00View SEC Filing  
5/1/2014John Maxim FerrariCFOSell10,000$102.20$1,022,000.00View SEC Filing  
5/1/2014Martine RothblattCEOSell9,066$101.84$923,281.44View SEC Filing  
5/1/2014Paul MahonEVPSell6,000$102.71$616,260.00View SEC Filing  
4/29/2014Roger JeffsCOOSell10,000$95.00$950,000.00View SEC Filing  
4/24/2014Martine RothblattCEOSell9,066$92.45$838,151.70View SEC Filing  
4/22/2014Roger JeffsCOOSell10,000$96.00$960,000.00View SEC Filing  
4/17/2014John Maxim FerrariCFOSell10,000$96.20$962,000.00View SEC Filing  
4/17/2014Martine RothblattCEOSell9,066$98.48$892,819.68View SEC Filing  
4/17/2014Paul MahonEVPSell6,000$98.37$590,220.00View SEC Filing  
4/15/2014Roger JeffsCOOSell10,000$95.06$950,600.00View SEC Filing  
4/10/2014Martine RothblattCEOSell9,066$96.18$871,967.88View SEC Filing  
4/8/2014Roger JeffsCOOSell10,000$95.00$950,000.00View SEC Filing  
4/4/2014Roger JeffsCOOSell10,000$93.22$932,200.00View SEC Filing  
4/3/2014Christopher CauseyDirectorSell1,500$95.67$143,505.00View SEC Filing  
4/3/2014John Maxim FerrariCFOSell10,000$93.22$932,200.00View SEC Filing  
4/3/2014Martine RothblattCEOSell9,066$93.74$849,846.84View SEC Filing  
4/3/2014Paul MahonEVPSell6,000$93.10$558,600.00View SEC Filing  
4/1/2014Roger JeffsCOOSell10,000$95.44$954,400.00View SEC Filing  
3/27/2014Martine RothblattCEOSell9,066$93.35$846,311.10View SEC Filing  
3/25/2014Roger JeffsCOOSell10,000$95.64$956,400.00View SEC Filing  
3/21/2014Roger JeffsCOOSell10,000$93.84$938,400.00View SEC Filing  
3/20/2014Christopher CauseyDirectorSell1,500$96.04$144,060.00View SEC Filing  
3/20/2014John Maxim FerrariCFOSell10,000$96.11$961,100.00View SEC Filing  
3/20/2014Martine RothblattCEOSell9,065$96.76$877,129.40View SEC Filing  
3/20/2014Paul MahonEVPSell6,000$96.81$580,860.00View SEC Filing  
3/18/2014Roger JeffsCOOSell10,000$96.51$965,100.00View SEC Filing  
3/13/2014Martine RothblattCEOSell3,833$95.64$366,588.12View SEC Filing  
3/7/2014Roger JeffsCOOSell10,000$99.02$990,200.00View SEC Filing  
3/6/2014Christopher PatuskyDirectorSell5,000$101.39$506,950.00View SEC Filing  
3/6/2014John Maxim FerrariCFOSell10,000$99.07$990,700.00View SEC Filing  
3/6/2014Martine RothblattCEOSell3,833$102.77$393,917.41View SEC Filing  
3/6/2014Paul MahonEVPSell6,000$101.93$611,580.00View SEC Filing  
2/28/2014Ray KurzweilDirectorSell15,000$101.42$1,521,300.00View SEC Filing  
2/27/2014Martine RothblattCEOSell3,833$100.68$385,906.44View SEC Filing  
2/21/2014Roger JeffsCOOSell10,000$104.89$1,048,900.00View SEC Filing  
2/20/2014Martine RothblattCEOSell3,833$103.91$398,287.03View SEC Filing  
2/20/2014Paul MahonEVPSell6,000$104.63$627,780.00View SEC Filing  
2/13/2014Martine RothblattCEOSell3,833$99.87$382,801.71View SEC Filing  
2/7/2014Roger JeffsCOOSell10,000$96.61$966,100.00View SEC Filing  
2/6/2014Martine RothblattCEOSell3,833$97.26$372,797.58View SEC Filing  
2/6/2014Paul MahonEVPSell6,000$97.41$584,460.00View SEC Filing  
2/6/2014Raymond DwekDirectorSell3,000$97.33$291,990.00View SEC Filing  
1/30/2014Martine RothblattCEOSell3,833$106.25$407,256.25View SEC Filing  
1/23/2014Martine RothblattCEOSell3,833$111.78$428,452.74View SEC Filing  
1/17/2014Roger JeffsCOOSell10,000$113.03$1,130,300.00View SEC Filing  
1/16/2014Martine RothblattCEOSell3,833$111.21$426,267.93View SEC Filing  
1/16/2014Paul MahonEVPSell6,000$111.98$671,880.00View SEC Filing  
1/9/2014Christopher PatuskyDirectorSell5,000$110.00$550,000.00View SEC Filing  
1/9/2014Martine RothblattCEOSell3,833$108.35$415,305.55View SEC Filing  
1/3/2014Roger JeffsCOOSell10,000$110.72$1,107,200.00View SEC Filing  
1/2/2014Martine RothblattCEOSell3,833$111.54$427,532.82View SEC Filing  
1/2/2014Paul MahonEVPSell6,000$110.78$664,680.00View SEC Filing  
1/2/2014Raymond DwekDirectorSell3,000$111.41$334,230.00View SEC Filing  
12/31/2013Martine RothblattCEOSell18,140$112.64$2,043,289.60View SEC Filing  
12/30/2013Martine RothblattCEOSell18,147$111.60$2,025,205.20View SEC Filing  
12/27/2013Martine RothblattCEOSell18,147$113.15$2,053,333.05View SEC Filing  
12/26/2013Martine RothblattCEOSell21,981$111.95$2,460,772.95View SEC Filing  
12/24/2013Martine RothblattCEOSell18,149$114.05$2,069,893.45View SEC Filing  
12/23/2013Martine RothblattCEOSell5,743$109.71$630,064.53View SEC Filing  
12/20/2013Martine RothblattCEOSell18,149$86.72$1,573,881.28View SEC Filing  
12/20/2013Roger JeffsCOOSell8,250$87.84$724,680.00View SEC Filing  
12/19/2013Martine RothblattCEOSell21,982$86.73$1,906,498.86View SEC Filing  
12/19/2013Paul MahonEVPSell6,000$86.45$518,700.00View SEC Filing  
12/18/2013Martine RothblattCEOSell18,149$86.36$1,567,347.64View SEC Filing  
12/17/2013Martine RothblattCEOSell12,251$86.49$1,059,588.99View SEC Filing  
12/6/2013Roger JeffsCOOSell10,000$90.97$909,700.00View SEC Filing  
12/5/2013Martine RothblattCEOSell3,833$89.79$344,165.07View SEC Filing  
12/5/2013Paul MahonEVPSell6,000$89.18$535,080.00View SEC Filing  
12/5/2013Raymond DwekDirectorSell3,000$90.13$270,390.00View SEC Filing  
11/21/2013Martine RothblattCEOSell3,833$92.49$354,514.17View SEC Filing  
11/21/2013Paul MahonEVPSell6,000$92.47$554,820.00View SEC Filing  
11/15/2013Roger JeffsCOOSell10,000$94.00$940,000.00View SEC Filing  
11/14/2013Christopher PatuskyDirectorSell5,500$91.65$504,075.00View SEC Filing  
11/14/2013Martine RothblattCEOSell3,833$91.60$351,102.80View SEC Filing  
11/7/2013Christopher PatuskyDirectorSell3,500$90.51$316,785.00View SEC Filing  
11/7/2013Martine RothblattCEOSell3,833$89.47$342,938.51View SEC Filing  
11/7/2013Paul MahonEVPSell6,000$89.60$537,600.00View SEC Filing  
11/1/2013Raymond DwekDirectorSell3,000$89.18$267,540.00View SEC Filing  
11/1/2013Roger JeffsCOOSell10,000$90.34$903,400.00View SEC Filing  
10/31/2013Martine A RothblattCEOSell3,833$86.89$333,049.37View SEC Filing  
10/24/2013Martine A RothblattCEOSell3,833$83.77$321,090.41View SEC Filing  
10/18/2013Roger JeffsCOOSell10,000$82.47$824,700.00View SEC Filing  
10/17/2013John Maxim FerrariCFOSell2,750$82.01$225,527.50View SEC Filing  
10/17/2013Martine A RothblattCEOSell3,833$81.84$313,692.72View SEC Filing  
10/17/2013Paul A MahonEVPSell6,000$81.79$490,740.00View SEC Filing  
10/10/2013Martine RothblattCEOSell3,833$82.58$316,529.14View SEC Filing  
10/4/2013Roger JeffsCOOSell10,000$85.48$854,800.00View SEC Filing  
10/3/2013Christopher CauseyDirectorSell1,500$83.15$124,725.00View SEC Filing  
10/3/2013John Maxim FerrariCFOSell4,500$84.67$381,015.00View SEC Filing  
10/3/2013Martine A RothblattCEOSell3,833$84.20$322,738.60View SEC Filing  
10/3/2013Paul A MahonEVPSell6,000$84.38$506,280.00View SEC Filing  
9/26/2013Martine RothblattCEOSell3,833$78.41$300,545.53View SEC Filing  
9/20/2013Roger JeffsCOOSell10,000$77.86$778,600.00View SEC Filing  
9/19/2013John Maxim FerrariCFOSell4,500$78.67$354,015.00View SEC Filing  
9/19/2013Martine RothblattCEOSell3,833$78.12$299,433.96View SEC Filing  
9/19/2013Paul MahonEVPSell6,000$78.02$468,120.00View SEC Filing  
9/12/2013Martine A RothblattCEOSell3,833$76.98$295,064.34View SEC Filing  
9/6/2013Roger JeffsCOOSell10,000$73.67$736,700.00View SEC Filing  
9/5/2013Christopher CauseyDirectorSell1,500$73.11$109,665.00View SEC Filing  
9/5/2013John Maxim FerrariCFOSell4,500$74.17$333,765.00View SEC Filing  
9/5/2013Martine A RothblattCEOSell3,833$73.63$282,223.79View SEC Filing  
9/5/2013Paul A MahonEVPSell6,000$73.29$439,740.00View SEC Filing  
8/29/2013Martine RothblattCEOSell3,833$72.76$278,889.08View SEC Filing  
8/22/2013Martine RothblattCEOSell3,833$72.06$276,205.98View SEC Filing  
8/16/2013Roger JeffsCOOSell10,000$71.21$712,100.00View SEC Filing  
8/15/2013John Maxim FerrariCFOSell4,500$71.14$320,130.00View SEC Filing  
8/15/2013Martine RothblattCEOSell3,833$71.58$274,366.14View SEC Filing  
8/15/2013Paul MahonEVPSell6,000$71.34$428,040.00View SEC Filing  
8/8/2013Martine RothblattCEOSell3,833$73.11$280,230.63View SEC Filing  
8/2/2013Roger JeffsCOOSell10,000$76.69$766,900.00View SEC Filing  
8/1/2013John Maxim FerrariCFOSell4,500$75.87$341,415.00View SEC Filing  
8/1/2013Martine A RothblattCEOSell3,833$75.97$291,193.01View SEC Filing  
8/1/2013Paul A MahonEVPSell6,000$75.91$455,460.00View SEC Filing  
8/1/2013Raymond DwekDirectorSell3,000$75.94$227,820.00View SEC Filing  
7/31/2013R Paul GrayDirectorSell7,500$74.93$561,975.00View SEC Filing  
7/25/2013Martine A RothblattCEOSell3,833$71.45$273,867.85View SEC Filing  
7/19/2013Roger JeffsCOOSell10,000$70.00$700,000.00View SEC Filing  
7/18/2013John Maxim FerrariCFOSell9,000$69.85$628,650.00View SEC Filing  
7/18/2013Martine A RothblattCEOSell3,833$68.96$264,323.68View SEC Filing  
7/18/2013Paul A MahonEVPSell6,000$69.15$414,900.00View SEC Filing  
7/11/2013Martine A RothblattCEOSell3,837$67.94$260,685.78View SEC Filing  
7/5/2013Christopher CauseyDirectorSell1,500$66.33$99,495.00View SEC Filing  
7/5/2013Martine A RothblattCEOSell3,863$67.28$259,902.64View SEC Filing  
7/5/2013Paul A MahonEVPSell6,000$67.04$402,240.00View SEC Filing  
7/5/2013Roger JeffsCOOSell10,000$67.21$672,100.00View SEC Filing  
6/21/2013Roger JeffsCOOSell10,000$63.34$633,400.00View SEC Filing  
6/20/2013John Maxim FerrariCFOSell4,500$63.22$284,490.00View SEC Filing  
6/20/2013Paul A MahonEVPSell6,000$63.29$379,740.00View SEC Filing  
6/7/2013Roger JeffsCOOSell10,000$67.00$670,000.00View SEC Filing  
6/6/2013John Maxim FerrariCFOSell4,500$64.84$291,780.00View SEC Filing  
6/6/2013Paul A MahonEVPSell6,000$63.84$383,040.00View SEC Filing  
6/6/2013Raymond DwekDirectorSell3,000$63.77$191,310.00View SEC Filing  
5/17/2013Roger JeffsCOOSell10,000$69.17$691,700.00View SEC Filing  
5/16/2013John Maxim FerrariCFOSell4,500$68.48$308,160.00View SEC Filing  
5/16/2013Paul A MahonEVPSell6,000$68.05$408,300.00View SEC Filing  
5/2/2013Paul A MahonEVPSell6,000$67.15$402,900.00View SEC Filing  
5/2/2013Raymond DwekDirectorSell3,000$66.75$200,250.00View SEC Filing  
4/11/2013Raymond DwekDirectorSell9,000$61.35$552,150.00View SEC Filing  
1/17/2013Paul A MahonEVPSell5,749$52.20$300,097.80View SEC Filing  
12/28/2012Martine A RothblattCEOBuy4,167$52.40$218,350.80View SEC Filing  
12/26/2012Martine A RothblattCEOBuy6,000$52.40$314,400.00View SEC Filing  
12/21/2012Martine A RothblattCEOBuy9,000$51.85$466,650.00View SEC Filing  
11/26/2012Christopher CauseyDirectorSell1,500$53.33$79,995.00View SEC Filing  
10/4/2012Christopher CauseyDirectorSell1,500$58.33$87,495.00View SEC Filing  
10/4/2012John Maxim FerrariCFOSell1,550$58.00$89,900.00View SEC Filing  
10/4/2012Paul A MahonEVPSell6,000$38.00$228,000.00View SEC Filing  
9/6/2012Christopher CauseyDirectorSell1,500$55.94$83,910.00View SEC Filing  
9/5/2012Christopher PatuskyDirectorSell2,000$55.47$110,940.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for United Therapeutics Corporation (NASDAQ UTHR)

Source:
DateHeadline
United Therapeutics Stock May Bottom Out After Strong Q3 ResultsUnited Therapeutics Stock May Bottom Out After Strong Q3 Results
seekingalpha.com - November 23 at 6:12 PM
Zacks: Brokerages Expect United Therapeutics Corporation (UTHR) to Post $3.36 EPSZacks: Brokerages Expect United Therapeutics Corporation (UTHR) to Post $3.36 EPS
www.americanbankingnews.com - November 23 at 3:08 AM
United Therapeutics PAH Drugs Exclusivity Period ExtendedUnited Therapeutics PAH Drug's Exclusivity Period Extended
finance.yahoo.com - November 23 at 1:43 AM
United Therapeutics Corp. (UTHR) PT Raised to $102 at UBS; Adcirca Generics Delayed Until Spring - StreetInsider.comUnited Therapeutics Corp. (UTHR) PT Raised to $102 at UBS; 'Adcirca Generics Delayed Until Spring' - StreetInsider.com
www.streetinsider.com - November 22 at 3:41 PM
United Therapeutics (UTHR) Secures Additional Six Months Of Regulatory Exclusivity For Adcirca - StreetInsider.comUnited Therapeutics (UTHR) Secures Additional Six Months Of Regulatory Exclusivity For Adcirca - StreetInsider.com
www.streetinsider.com - November 20 at 3:38 PM
United Therapeutics (UTHR) Secures Additional Six Months Of Regulatory Exclusivity For AdcircaUnited Therapeutics (UTHR) Secures Additional Six Months Of Regulatory Exclusivity For Adcirca
www.streetinsider.com - November 20 at 11:57 AM
Insider Selling: United Therapeutics Corporation (UTHR) CEO Sells 7,061 Shares of StockInsider Selling: United Therapeutics Corporation (UTHR) CEO Sells 7,061 Shares of Stock
www.americanbankingnews.com - November 17 at 8:11 PM
SteadyMed Ltd. (STDY) Reports Invalidation of United Therapeutics (UTHR) '393 ...SteadyMed Ltd. (STDY) Reports Invalidation of United Therapeutics (UTHR) '393 ...
www.streetinsider.com - November 14 at 8:21 PM
SteadyMed Ltd. (STDY) Reports Invalidation of United Therapeutics (UTHR) 393 Patent with Favorable Ruling from ... - StreetInsider.comSteadyMed Ltd. (STDY) Reports Invalidation of United Therapeutics (UTHR) '393' Patent with Favorable Ruling from ... - StreetInsider.com
www.streetinsider.com - November 14 at 3:20 PM
SteadyMed Receives Favorable Ruling from U.S. Court of Appeals for the Federal CircuitSteadyMed Receives Favorable Ruling from U.S. Court of Appeals for the Federal Circuit
finance.yahoo.com - November 14 at 3:20 PM
United Therapeutics Corporation (UTHR) CEO Martine A. Rothblatt Sells 1,260 SharesUnited Therapeutics Corporation (UTHR) CEO Martine A. Rothblatt Sells 1,260 Shares
www.americanbankingnews.com - November 13 at 4:51 PM
FXH, HOLX, UTHR, MD: ETF Outflow Alert - NasdaqFXH, HOLX, UTHR, MD: ETF Outflow Alert - Nasdaq
www.nasdaq.com - November 13 at 3:19 PM
United Therapeutics Corp. breached its 50 day moving average in a Bearish Manner : UTHR-US : November 10, 2017United Therapeutics Corp. breached its 50 day moving average in a Bearish Manner : UTHR-US : November 10, 2017
finance.yahoo.com - November 12 at 1:00 PM
United Therapeutics Corporation (UTHR) Director Sells $70,760.00 in StockUnited Therapeutics Corporation (UTHR) Director Sells $70,760.00 in Stock
www.americanbankingnews.com - November 7 at 7:10 PM
ETFs with exposure to United Therapeutics Corp. : November 6, 2017ETFs with exposure to United Therapeutics Corp. : November 6, 2017
finance.yahoo.com - November 7 at 12:57 PM
Zacks: Brokerages Anticipate United Therapeutics Corporation (UTHR) Will Post Quarterly Sales of $406.21 MillionZacks: Brokerages Anticipate United Therapeutics Corporation (UTHR) Will Post Quarterly Sales of $406.21 Million
www.americanbankingnews.com - November 6 at 6:28 AM
United Therapeutics Corporation (UTHR) Receives Average Recommendation of "Hold" from BrokeragesUnited Therapeutics Corporation (UTHR) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 5 at 7:33 PM
 Analysts Expect United Therapeutics Corporation (UTHR) Will Announce Earnings of $3.41 Per Share Analysts Expect United Therapeutics Corporation (UTHR) Will Announce Earnings of $3.41 Per Share
www.americanbankingnews.com - November 4 at 3:18 AM
Martine A. Rothblatt Sells 1,269 Shares of United Therapeutics Corporation (UTHR) StockMartine A. Rothblatt Sells 1,269 Shares of United Therapeutics Corporation (UTHR) Stock
www.americanbankingnews.com - November 2 at 5:58 PM
ETFs with exposure to United Therapeutics Corp. : October 27, 2017ETFs with exposure to United Therapeutics Corp. : October 27, 2017
finance.yahoo.com - October 28 at 5:53 PM
FY2018 EPS Estimates for United Therapeutics Corporation (UTHR) Decreased by Leerink SwannFY2018 EPS Estimates for United Therapeutics Corporation (UTHR) Decreased by Leerink Swann
www.americanbankingnews.com - October 27 at 5:24 PM
Martine A. Rothblatt Sells 1,263 Shares of United Therapeutics Corporation (UTHR) StockMartine A. Rothblatt Sells 1,263 Shares of United Therapeutics Corporation (UTHR) Stock
www.americanbankingnews.com - October 27 at 8:27 AM
United Therapeutics (UTHR) Q3 Earnings Up Y/Y, Revenues Beat - NasdaqUnited Therapeutics (UTHR) Q3 Earnings Up Y/Y, Revenues Beat - Nasdaq
www.nasdaq.com - October 27 at 7:28 AM
FY2017 Earnings Forecast for United Therapeutics Corporation (UTHR) Issued By Jefferies GroupFY2017 Earnings Forecast for United Therapeutics Corporation (UTHR) Issued By Jefferies Group
www.americanbankingnews.com - October 27 at 6:52 AM
United Therapeutics Corporation (UTHR) Given "Hold" Rating at HC WainwrightUnited Therapeutics Corporation (UTHR) Given "Hold" Rating at HC Wainwright
www.americanbankingnews.com - October 26 at 5:24 PM
United Therapeutics Corporation to Post FY2018 Earnings of $11.41 Per Share, Jefferies Group Forecasts (UTHR)United Therapeutics Corporation to Post FY2018 Earnings of $11.41 Per Share, Jefferies Group Forecasts (UTHR)
www.americanbankingnews.com - October 26 at 2:30 PM
United Therapeutics (UTHR) Q3 Earnings Up Y/Y, Revenues BeatUnited Therapeutics (UTHR) Q3 Earnings Up Y/Y, Revenues Beat
www.zacks.com - October 26 at 12:06 PM
Edited Transcript of UTHR earnings conference call or presentation 25-Oct-17 1:00pm GMTEdited Transcript of UTHR earnings conference call or presentation 25-Oct-17 1:00pm GMT
finance.yahoo.com - October 26 at 12:05 PM
United Therapeutics Corp. :UTHR-US: Earnings Analysis: Q3, 2017 By the Numbers : October 26, 2017United Therapeutics Corp. :UTHR-US: Earnings Analysis: Q3, 2017 By the Numbers : October 26, 2017
finance.yahoo.com - October 26 at 12:05 PM
Q4 2017 EPS Estimates for United Therapeutics Corporation Boosted by Analyst (UTHR)Q4 2017 EPS Estimates for United Therapeutics Corporation Boosted by Analyst (UTHR)
www.americanbankingnews.com - October 26 at 10:56 AM
United Therapeutics (UTHR) CEO Martine Rothblatt on Q3 2017 Results - Earnings Call Transcript - Seeking AlphaUnited Therapeutics' (UTHR) CEO Martine Rothblatt on Q3 2017 Results - Earnings Call Transcript - Seeking Alpha
seekingalpha.com - October 25 at 3:50 PM
United Therapeutics Corporation Reports Third Quarter 2017 Financial ResultsUnited Therapeutics Corporation Reports Third Quarter 2017 Financial Results
finance.yahoo.com - October 25 at 3:50 PM
United Therapeutics beats Street 3Q forecastsUnited Therapeutics beats Street 3Q forecasts
finance.yahoo.com - October 25 at 3:50 PM
United Therapeutics Corporation to Host Earnings CallUnited Therapeutics Corporation to Host Earnings Call
finance.yahoo.com - October 25 at 3:50 PM
Corporate News Blog - United Therapeutics Receives FDA Approval of Third Generation Nebulizer for Tyvaso Inhalation SystemCorporate News Blog - United Therapeutics Receives FDA Approval of Third Generation Nebulizer for Tyvaso Inhalation System
finance.yahoo.com - October 25 at 3:50 PM
United Therapeutics Corporation (UTHR) Posts Quarterly  Earnings Results, Beats Estimates By $2.58 EPSUnited Therapeutics Corporation (UTHR) Posts Quarterly Earnings Results, Beats Estimates By $2.58 EPS
www.americanbankingnews.com - October 25 at 10:33 AM
United Therapeutics Announces FDA Approval Of Third Generation ... - PR Newswire (press release)United Therapeutics Announces FDA Approval Of Third Generation ... - PR Newswire (press release)
www.prnewswire.com - October 25 at 2:07 AM
United Therapeutics lands FDA approval linked to drug at center of patent lawsuits - Triangle Business JournalUnited Therapeutics lands FDA approval linked to drug at center of patent lawsuits - Triangle Business Journal
www.bizjournals.com - October 25 at 2:07 AM
United Therapeutics lands FDA approval linked to drug at center of patent lawsuitsUnited Therapeutics lands FDA approval linked to drug at center of patent lawsuits
finance.yahoo.com - October 24 at 11:52 AM
United Therapeutics (UTHR) Granted FDA Approval Of Third Generation Nebulizer For Tyvaso Inhalation SystemUnited Therapeutics (UTHR) Granted FDA Approval Of Third Generation Nebulizer For Tyvaso Inhalation System
www.streetinsider.com - October 23 at 8:48 AM
United Therapeutics (UTHR) Granted FDA Approval Of Third Generation Nebulizer For Tyvaso Inhalation System - StreetInsider.comUnited Therapeutics (UTHR) Granted FDA Approval Of Third Generation Nebulizer For Tyvaso Inhalation System - StreetInsider.com
www.streetinsider.com - October 23 at 8:48 AM
United Therapeutics Announces FDA Approval Of Third Generation Nebulizer For The Tyvaso® Inhalation SystemUnited Therapeutics Announces FDA Approval Of Third Generation Nebulizer For The Tyvaso® Inhalation System
finance.yahoo.com - October 23 at 8:48 AM
United Therapeutics Corporation (UTHR) CEO Martine A. Rothblatt Sells 1,265 SharesUnited Therapeutics Corporation (UTHR) CEO Martine A. Rothblatt Sells 1,265 Shares
www.americanbankingnews.com - October 20 at 7:44 PM
United Therapeutics Corporation To Report Third Quarter 2017 Financial Results Before The Market Opens On ... - PR Newswire (press release)United Therapeutics Corporation To Report Third Quarter 2017 Financial Results Before The Market Opens On ... - PR Newswire (press release)
www.prnewswire.com - October 20 at 9:45 AM
United Therapeutics Corporation To Report Third Quarter 2017 Financial Results Before The Market Opens On Wednesday, October 25, 2017United Therapeutics Corporation To Report Third Quarter 2017 Financial Results Before The Market Opens On Wednesday, October 25, 2017
finance.yahoo.com - October 20 at 9:45 AM
United Therapeutics Corporation (UTHR) to Release Earnings on WednesdayUnited Therapeutics Corporation (UTHR) to Release Earnings on Wednesday
www.americanbankingnews.com - October 18 at 3:44 AM
$430.87 Million in Sales Expected for United Therapeutics Corporation (UTHR) This Quarter$430.87 Million in Sales Expected for United Therapeutics Corporation (UTHR) This Quarter
www.americanbankingnews.com - October 17 at 6:50 AM
United Therapeutics Corporation (UTHR) Receives Consensus Recommendation of "Hold" from BrokeragesUnited Therapeutics Corporation (UTHR) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 11 at 8:08 PM
Why United Therapeutics’ Revenue May Rise in 2017Why United Therapeutics’ Revenue May Rise in 2017
finance.yahoo.com - October 10 at 8:00 AM
United Therapeutics’s Net Profit Margins Are Expected to NarrowUnited Therapeutics’s Net Profit Margins Are Expected to Narrow
finance.yahoo.com - October 10 at 8:00 AM

Social Media

Financials

Chart

United Therapeutics Corporation (NASDAQ UTHR) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.